Cognitive decline including mild cognitive impairment describes a heterogeneous condition with cognitive changes between normal ageing and dementia. Cognitive impairment can be promoted or caused by treatable somatic factors. In this review, three important cardiovascular risk factors, diabetes mellitus, hypercholesterolaemia and hypertension, and their association with cognitive decline, are assessed. Though there are many hints of a causal association between diabetes mellitus and the development of cognitive decline, definitive proof of a protective effect of antidiabetic treatment by controlled or randomised placebo-controlled studies is needed. In midlife, elevated cholesterol levels comprise a risk factor for cognitive decline. In elderly subjects, cholesterol levels decline and are not clearly associated with cognitive impairment. The evidence for treatment of hypercholesterolaemia by statins solely for prevention of cognitive decline remains unclear. There is an age-dependent relationship between blood pressure and cognitive impairment. Midlife hypertension is associated with an increased risk of developing cognitive decline and antihypertensive treatment may therefore be beneficial, whereas hypertension later in life does not carry the same risk of cognitive dysfunction. Diagnosis of these somatic factors is essential in cognitive impairment, as diligent treatment may improve cognitive performance and postpone the manifestation of dementia.
Gauthier S., Reisberg B., Zaudig M. et al. Mild cognitive impairment. Lancet2006;367:1262-70.
2.
Panza F., D’Introno A., Colacicco AM et al. Current epidemiology of mild cognitive impairment and other predementia syndromes. Am J Geriatr Psychiatry2005;13:633-44.
3.
Luck T., Riedel-Heller SG, Kaduszkiewicz H. et al. Mild cognitive impairment in general practice: age-specific prevalence and correlate results from the German study on ageing, cognition and dementia in primary care patients (AgeCoDe). Dement Geriatr Cogn Disord2007;24:307-16.
4.
Mitchell AJ, Shiri-Feshki M.Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand2009;119:252-65.
5.
Forstl H., Bickel H., Frolich L. et al. [MCI-plus: mild cognitive impairment with rapid progression. Part I: prevention and therapy]Dtsch Med Wochenschr2009;134:39-44.
6.
Etgen T., Bronner M., Sander D. et al. Somatic factors in cognitive impairment. Fortschr Neurol Psychiatr2009;77:72-82.
7.
Erkinjuntti T., Gauthier S.The concept of vascular cognitive impairment . Front Neurol Neurosci2009;24:79-85.
8.
Brownlee M.Biochemistry and molecular cell biology of diabetic complications. Nature2001;414:813-20.
9.
Farris W., Mansourian S., Chang Y. et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A2003;100:4162-7.
10.
Biessels GJ , Kappelle LJIncreased risk of Alzheimer’s disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?Biochem Soc Trans2005;33:1041-4.
11.
den Heijer T., Vermeer SE, van Dijk EJ et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia2003;46:1604-10.
12.
Biessels GJ , Koffeman A., Scheltens P.Diabetes and cognitive impairment. Clinical diagnosis and brain imaging in patients attending a memory clinic. J Neurol2006;253:477-82.
13.
Sonnen JA, Larson EB, Brickell K. et al. Different patterns of cerebral injury in dementia with or without diabetes. Arch Neurol2009;66:315-22.
14.
Strachan MW , Deary IJ, Ewing FM et al. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care1997;20:438-45.
15.
Biessels GJ , Staekenborg S., Brunner E. et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol2006;5:64-74.
16.
Gregg EW, Yaffe K., Cauley JA et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group . Arch Intern Med2000;160:174-80.
17.
Logroscino G., Kang JH, Grodstein F.Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ2004 ;328:548.
18.
Yaffe K., Blackwell T., Kanaya AM et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology2004;63:658-63.
19.
Okereke OI, Kang JH, Cook NR et al. Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults. J Am Geriatr Soc2008;56:1028-36.
20.
Luchsinger JA, Reitz C., Patel B. et al. Relation of diabetes to mild cognitive impairment. Arch Neurol2007;64:570-5.
21.
Whitmer RA, Karter AJ, Yaffe K. et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA2009;301:1565-72.
22.
Bruce DG, Davis WA, Casey GP et al. Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the Fremantle Diabetes Study. Diabetologia2009;52:1808-15.
23.
Hartmann T. , Kuchenbecker J., Grimm MOAlzheimer’s disease: the lipid connection . J Neurochem2007;103(suppl 1):159-70.
24.
Pappolla MA , Bryant-Thomas TK, Herbert D. et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology2003;61:199-205.
25.
Roher AE, Esh C., Kokjohn TA et al. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer’s disease. Arterioscler Thromb Vasc Biol2003;23:2055-62.
26.
Kivipelto M. , Helkala EL, Hanninen T. et al. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology2001;56:1683-9.
27.
Whitmer RA, Sidney S., Selby J. et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology2005;64:277-81.
28.
Dufouil C., Richard F., Fievet N. et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology2005;64:1531-8.
29.
Solfrizzi V. , Panza F., Colacicco AM et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology2004;63: 1882-91.
30.
Li G., Shofer JB, Kukull WA et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology2005;65:1045-50.
31.
Reitz C., Tang MX, Luchsinger J. et al. Relation of plasma lipids to Alzheimer disease and vascular dementia . Arch Neurol2004;61: 705-14.
32.
Panza F., Capurso C., D’Introno A. et al. Total cholesterol levels and the risk of mild cognitive impairment and Alzheimer’s disease. J Am Geriatr Soc2007;55:133-5.
33.
Wolozin B., Kellman W., Ruosseau P. et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol2000;57:1439-43.
34.
Jick H., Zornberg GL, Jick SS et al. Statins and the risk of dementia. Lancet2000;356:1627-31.
35.
Cramer C., Haan MN, Galea S. et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology2008;71:344-50.
36.
Haag MD, Hofman A., Koudstaal PJ et al. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry2009;80:13-7.
37.
Group Hpsc.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7-22.
38.
Shepherd J., Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet2002;360:1623-30.
39.
McGuinness B., Craig D., Bullock R. et al. Statins for the prevention of dementia . Cochrane Database Syst Rev2009;(2):CD003160.
40.
Sparks L.Statins and cognitive function. J Neurol Neurosurg Psychiatry2009;80:1-2.
41.
Spence JDCerebral consequences of hypertension: where do they lead?J Hypertens Suppl1996;14:S139-45.
42.
Qiu C., Winblad B., Fratiglioni L.The age-dependent relation of blood pressure to cognitive function and dementia . Lancet Neurol2005;4:487-99.
43.
Hoffman LB, Schmeidler J., Lesser GT et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology2009 ;72:1720-6.
44.
Birns J., Kalra L.Cognitive function and hypertension. J Hum Hypertens2008.
45.
Prince MJ, Bird AS, Blizard RA et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s trial of hypertension in older adults. BMJ1996;312:801-5.
46.
Forette F., Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet1998;352:1347-51.
47.
Forette F., Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med2002;162: 2046-52.
48.
Applegate WB , Pressel S., Wittes J. et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med1994 ;154:2154-60.
49.
Lithell H., Hansson L., Skoog I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens2003;21:875-86.
50.
Tzourio C., Anderson C., Chapman N. et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med2003;163:1069-75.
51.
Peters R., Beckett N., Forette F. et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol2008 ;7:683-9.
52.
McGuinness B., Todd S., Passmore P. et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev2009 ;(4):CD004034.
53.
Poon IOEffects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy2008;28: 366-75.
54.
Takeda S., Sato N., Takeuchi D. et al. Angiotensin receptor blocker prevented β-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension2009;54:1345-52.
55.
Sink KM, Leng X., Williamson J. et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the cardiovascular health study. Arch Intern Med2009;169:1195-202.
56.
Birns J., Markus H., Kalra L.Blood pressure reduction for vascular risk: is there a price to be paid?Stroke2005;36:1308-13.
57.
Kennelly SP , Lawlor BA, Kenny RABlood pressure and the risk for dementia: a double edged sword. Ageing Res Rev2009;8:61-70.
58.
Haag MD, Hofman A., Koudstaal PJ et al. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology2009;72:1727-34.
59.
Skoog I., Lernfelt B., Landahl S. et al. 15-year longitudinal study of blood pressure and dementia. Lancet1996;347:1141-5.
